Advertisement
HCA vs MD
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HCA is a Buy and MD is a Buy.
HCA in +6.25% Uptrend, rising for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HCA advanced for three days, in 247 of 347 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Aroon Indicator entered an Uptrend today. In 206 of 322 cases where HCA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for HCA moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 49 similar instances where the indicator moved out of overbought territory. In 33 of the 49 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 66 cases where HCA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 59%.
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HCA as a result. In 54 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.
The Moving Average Convergence Divergence Histogram (MACD) for HCA turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 27 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HCA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
HCA broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 29 (best 1 - 100 worst), indicating outstanding price growth. HCA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 36 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-15.246) is normal, around the industry mean (204.016). P/E Ratio (15.477) is within average values for comparable stocks, (19.314). Projected Growth (PEG Ratio) (1.323) is also within normal values, averaging (2.498). Dividend Yield (0.007) settles around the average of (0.094) among similar stocks. P/S Ratio (1.264) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
MD's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for MD turned positive on October 08, 2026. Looking at past instances where MD's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on MD as a result. In 69 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
MD moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MD crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 72%.
Following a +5.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where MD advanced for three days, in 193 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
The Aroon Indicator entered an Uptrend today. In 134 of 198 cases where MD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
MD broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. MD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.832) is normal, around the industry mean (204.016). P/E Ratio (14.418) is within average values for comparable stocks, (19.314). Projected Growth (PEG Ratio) (0.120) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.094) among similar stocks. P/S Ratio (1.119) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 89 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
HCA | MD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 20 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | 63 Fair valued | |
PROFIT vs RISK RATING 1..100 | 36 | 89 | |
SMR RATING 1..100 | 45 | 46 | |
PRICE GROWTH RATING 1..100 | 29 | 36 | |
P/E GROWTH RATING 1..100 | 64 | 17 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
HCA's Valuation (62) in the Hospital Or Nursing Management industry is in the same range as MD (63) in the Medical Or Nursing Services industry. This means that HCA’s stock grew similarly to MD’s over the last 12 months.
HCA's Profit vs Risk Rating (36) in the Hospital Or Nursing Management industry is somewhat better than the same rating for MD (89) in the Medical Or Nursing Services industry. This means that HCA’s stock grew somewhat faster than MD’s over the last 12 months.
HCA's SMR Rating (45) in the Hospital Or Nursing Management industry is in the same range as MD (46) in the Medical Or Nursing Services industry. This means that HCA’s stock grew similarly to MD’s over the last 12 months.
HCA's Price Growth Rating (29) in the Hospital Or Nursing Management industry is in the same range as MD (36) in the Medical Or Nursing Services industry. This means that HCA’s stock grew similarly to MD’s over the last 12 months.
MD's P/E Growth Rating (17) in the Medical Or Nursing Services industry is somewhat better than the same rating for HCA (64) in the Hospital Or Nursing Management industry. This means that MD’s stock grew somewhat faster than HCA’s over the last 12 months.
| HCA | MD | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 67% | 1 day ago 74% |
| Stochastic ODDS (%) | 1 day ago 59% | 1 day ago 71% |
| Momentum ODDS (%) | 1 day ago 61% | 1 day ago 72% |
| MACD ODDS (%) | 1 day ago 56% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 70% | 1 day ago 64% |
| TrendMonth ODDS (%) | 1 day ago 68% | 1 day ago 65% |
| Advances ODDS (%) | 6 days ago 71% | 2 days ago 65% |
| Declines ODDS (%) | 1 day ago 62% | 8 days ago 71% |
| BollingerBands ODDS (%) | 1 day ago 45% | 1 day ago 76% |
| Aroon ODDS (%) | 1 day ago 64% | 1 day ago 68% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HCA’s FA Score shows that 1 FA rating(s) are green while MD’s FA Score has 1 green FA rating(s).
- HCA’s FA Score: 1 green, 4 red.
- MD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HCA’s TA Score shows that 2 TA indicator(s) are bullish while MD’s TA Score has 6 bullish TA indicator(s).
- HCA’s TA Score: 2 bullish, 6 bearish.
- MD’s TA Score: 6 bullish, 4 bearish.
Price Growth
HCA (@Hospital/Nursing Management) experienced а +2.87% price change this week, while MD (@Hospital/Nursing Management) price change was +6.10% for the same time period.
The average weekly price growth across all stocks in the @Hospital/Nursing Management industry was -0.48%. For the same industry, the average monthly price growth was +2.49%, and the average quarterly price growth was +11.67%.
Reported Earning Dates
HCA is expected to report earnings on Feb 02, 2027.
MD is expected to report earnings on Feb 18, 2027.
Industries' Descriptions
@Hospital/Nursing Management (-0.48% weekly)Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.
Advertisement
MD and
Correlation & Price change
A.I.dvisor indicates that over the last year, MD has been loosely correlated with NHC. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if MD jumps, then NHC could also see price increases.